Connect Biopharma Holdings Limited (CNTB)
| Market Cap | 121.54M |
| Revenue (ttm) | 2.95M +50.3% |
| Net Income | -68.99M |
| EPS | -1.19 |
| Shares Out | 62.97M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,759,862 |
| Open | 2.830 |
| Previous Close | 2.760 |
| Day's Range | 1.900 - 2.930 |
| 52-Week Range | 1.230 - 3.820 |
| Beta | -0.18 |
| Analysts | Strong Buy |
| Price Target | 7.25 (+275.65%) |
| Earnings Date | Aug 12, 2026 |
About CNTB
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Rα in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.
Financial Performance
In 2025, CNTB's revenue was $64,000, a decrease of -99.75% compared to the previous year's $26.03 million. Losses were -$55.48 million, 255.0% more than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for CNTB stock is "Strong Buy." The 12-month stock price target is $7.25, which is an increase of 275.65% from the latest price.
News
Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on trans...
Connect Biopharma price target raised to $7 from $6 at Canaccord
Canaccord analyst Edward Nash raised the firm’s price target on Connect Biopharma (CNTB) to $7 from $6 and keeps a Buy rating on the shares. The firm updated its model…
Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update
– Completed enrollment in Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD – – Expect to report topline results from both Phase 2 Seabreeze STAT studies in September 2026 – – ...
Connect Biopharma Holdings Earnings release: Q2 2026
Connect Biopharma Holdings released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Connect Biopharma Holdings Quarterly report: Q2 2026
Connect Biopharma Holdings has published its Q2 2026 quarterly earnings report on August 12, 2026.
Connect Biopharma Holdings Slides: Corporate presentation
Connect Biopharma Holdings has posted slides in relation to its latest quarterly earnings report, which was published on July 14, 2026.
Connect Biopharma initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Connect Biopharma (CNTB) with an Outperform rating and $8 price target Connect Biopharma is a single-asset story built on rademikibart, a next-generation human IgG4 a...
Connect Biopharma initiated with an Overweight at Piper Sandler
Piper Sandler initiated coverage of Connect Biopharma (CNTB) with an Overweight rating and $7 price target The firm cites rademikibart’s “differentiated mechanism” and potentially unique position as t...
Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
– On track to also complete enrollment in the Seabreeze STAT COPD study this month – – Expect to report topline data from Seabreeze STAT Asthma study in early September 2026 – – Strong balance sheet w...
Connect Biopharma initiated with a Buy at Canaccord
Canaccord analyst Edward Nash initiated coverage of Connect Biopharma (CNTB) with a Buy rating and $6 price target
Connect Biopharma initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Connect Biopharma (CNTB) with an Overweight rating and $4 price target The company’s Phase 2 SEABREEZE STAT readouts in acute asthma and acute COPD are…
Connect Biopharma initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Olivia Brayer initiated coverage of Connect Biopharma (CNTB) with an Overweight rating and $4 price target
Connect Biopharma Holdings Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
Rademikibart shows rapid, durable improvements in asthma and COPD, with unique bronchodilation and eosinophil-lowering effects. SEABREEZE’s mid-2026 readout will guide phase III plans, and commercialization will focus on seamless acute-to-chronic care transitions.
Connect Biopharma files to sell 6.13M ordinary shares for holders
08:33 EDT Connect Biopharma (CNTB) files to sell 6.13M ordinary shares for holders
Connect Biopharma Holdings Registration statement: Registration filing
Connect Biopharma Holdings filed a registration statement on May 15, 2026, providing details about a securities offering with the SEC.
Connect Biopharma Holdings Slides: Corporate presentation
Connect Biopharma Holdings has posted slides in relation to its latest quarterly earnings report, which was published on May 14, 2026.
Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transfo...
Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update
– Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD continuing as planned based on independent DMC review of pre-specified interim analysis –
Connect Biopharma Holdings Earnings release: Q1 2026
Connect Biopharma Holdings released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Connect Biopharma Holdings Quarterly report: Q1 2026
Connect Biopharma Holdings has published its Q1 2026 quarterly earnings report on May 12, 2026.
Connect Biopharma announces enrollment in Seabreeze STAT study
Connect Biopharma (CNTB) announced that the independent Data Monitoring Committee overseeing its Phase 2 Seabreeze STAT asthma and COPD trials evaluating rademikibart, the company’s next-generation an...
Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis
SAN DIEGO, April 23, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on trans...
Connect Biopharma director buys $4.0M in common stock
In a regulatory filing, Connect Biopharma (CNTB) disclosed that its director James Huang bought 1.16M shares of common stock on March 31 in a total transaction size of $4.0M. Shares…
Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update
– Released positive topline data from Phase 1 study of IV rademikibart in patients with asthma or COPD – – Results from Phase 3 study of rademikibart in moderate-to-severe AD presented in late-breakin...
Connect Biopharma Holdings Annual report: Q4 2025
Connect Biopharma Holdings has published its Q4 2025 annual report on March 31, 2026.